2024-10-26 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis

**Company Overview:** Abbott Laboratories is a global healthcare company that develops, manufactures, and markets a wide range of medical devices, pharmaceuticals, and nutrition products.

**1. Performance vs. S&P 500:**

ABT has underperformed the S&P 500 (VOO) by **-26.83%**. This means ABT's cumulative return is **15.19%** lower than the S&P 500 based on its historical performance relative to the S&P 500.

**2. Recent Price Action:**

* **Closing Price:** $116.54 (Last Market: $113.94)
* **5-day Moving Average:** $117.39
* **20-day Moving Average:** $115.53
* **60-day Moving Average:** $113.68

The current price is slightly below the 5-day moving average, suggesting potential short-term weakness. However, it's above the 20-day and 60-day moving averages, indicating a longer-term uptrend.

**3. Technical Indicators:**

* **RSI:** 65.83: This indicates that the stock is in overbought territory.
* **PPO:** 0.02:  This suggests that the stock's momentum is slightly positive but not extremely strong.
* **Delta_Previous_Relative_Divergence:** 3.96 (+): This indicates a short-term upward trend. 
* **Expected Return:** 0.0%. This suggests that ABT is expected to perform in line with the S&P 500 over the long term (2 years+).

**4. Recent Earnings and Outlook:**

| Date       | EPS    | Revenue       |
|------------|--------|---------------|
| 2024-07-31 | 0.74   | $10.38 B      |
| 2024-05-02 | 0.7    | $9.96 B       |
| 2023-11-01 | 0.82   | $10.14 B      |
| 2023-08-03 | 0.79   | $9.98 B       |
| 2024-07-31 | 0.79   | $9.98 B       |

The most recent earnings for the quarter ending July 31, 2024, were **$0.74 EPS** on **$10.38B revenue**. This was slightly better than analysts' expectations, which were $0.72 EPS and $10.32B revenue.

**5. News and Recent Issues:**

* **Earnings News:**  
    * A recent earnings call (analyzed from Shacknews, etc.) should be reviewed for any specific news that might impact ABT's price. 
* **Market Outlook:** 
    * Check FINBOLD and other reputable sources for the recent market outlook for ABT, including analyst opinions and performance highlights.  

**6. Overall Analysis:**

ABT has underperformed the S&P 500 in the past, but its recent earnings beat expectations.  The stock is currently in overbought territory and its technical indicators suggest a short-term upward trend. However, the expected long-term return is in line with the S&P 500. Investors should consider recent news, analyst opinions, and the overall market outlook before making any investment decisions.

**7. Report in English:**

This analysis provides a comprehensive overview of ABT's current performance, recent price action, technical indicators, earnings, and news. It suggests that ABT is a solid, established healthcare company with a track record of steady performance. However, its recent underperformance and current overbought condition may create some uncertainty for investors. Further research and analysis, focusing on recent news, analyst opinions, and overall market trends, are essential for making informed investment decisions. 
